J. Goldman & Co’s Repros Therapeutics Inc. RPRX Stock Holding History

J. Goldman & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-101,881	Closed	-$779K	–	354
2015 Q2	$728K	Sell	101,881 -38,119	-27%	-$297K	0.04%	198
2015 Q1	$1.2M	Buy	140,000 +14,000	+11%	+$125K	0.07%	214
2014 Q4	$1.26M	Buy	126,000 +101,000	+404%	+$861K	0.15%	138
2014 Q3	$248K	Buy	+25,000	New	+$370K	0.02%	263
2014 Q1	–	Sell	-45,000	Closed	-$871K	–	369
2013 Q4	$823K	Buy	+45,000	New	+$850K	0.1%	170
2013 Q3	–	Sell	-94,875	Closed	-$2.03M	–	410
2013 Q2	$1.75M	Buy	+94,875	New	+$1.68M	0.18%	147

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

J. Goldman & Co's RPRX Position: Q3 2015 in Review

J. Goldman & Co sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 101,881 shares — an estimated $779K sold.

J. Goldman & Co first reported a position in RPRX in Q2 2013 and held it in 6 quarters. The position peaked at $1.75M in Q2 2013. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

J. Goldman & Co reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
J. Goldman & Co sold 101,881 Repros Therapeutics Inc. shares in Q3 2015, an estimated $779K.
J. Goldman & Co first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 6 quarters.
J. Goldman & Co's Repros Therapeutics Inc. position peaked at $1.75M in Q2 2013.
58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on J. Goldman & Co's 13F filing for Q3 2015, filed 16 Nov 2015.